<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Compugen Ltd. — News on 6ix</title>
<link>https://6ix.com/company/compugen</link>
<description>Latest news and press releases for Compugen Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 04 May 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/compugen" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683554ad78dffbe2df0e9002.webp</url>
<title>Compugen Ltd.</title>
<link>https://6ix.com/company/compugen</link>
</image>
<item>
<title>Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026</title>
<link>https://6ix.com/company/compugen/news/compugen-to-release-first-quarter-2026-results-on-monday-may-18-2026</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-to-release-first-quarter-2026-results-on-monday-may-18-2026</guid>
<pubDate>Mon, 04 May 2026 11:00:00 GMT</pubDate>
<description>Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.</description>
</item>
<item>
<title>Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/compugen/news/compugen-to-participate-in-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-to-participate-in-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation will take place on Monday, April 13, 2026, at 8:45-9:25 AM ET.</description>
</item>
<item>
<title>Compugen Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/compugen/news/compugen-reports-fourth-quarter-and-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-reports-fourth-quarter-and-full-year-2025-results</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending</description>
</item>
<item>
<title>Compugen to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/compugen/news/compugen-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>HOLON, Israel, Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in</description>
</item>
<item>
<title>Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026</title>
<link>https://6ix.com/company/compugen/news/compugen-release-fourth-quarter-full-120000157</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-release-fourth-quarter-full-120000157</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.</description>
</item>
<item>
<title>Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors</title>
<link>https://6ix.com/company/compugen/news/compugen-announces-appointment-michele-holcomb-120000765</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-announces-appointment-michele-holcomb-120000765</guid>
<pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
<description>Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D., as a new independent director, effective February 11, 2026.</description>
</item>
<item>
<title>Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million</title>
<link>https://6ix.com/company/compugen/news/compugen-monetizes-portion-rilvegostomig-future-royalties-astrazeneca-90-million-2025</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-monetizes-portion-rilvegostomig-future-royalties-astrazeneca-90-million-2025</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential</description>
</item>
<item>
<title>Compugen Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/compugen/news/compugen-reports-third-quarter-2025-results-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-reports-third-quarter-2025-results-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform</description>
</item>
<item>
<title>Compugen to Participate in Stifel 2025 Healthcare Conference</title>
<link>https://6ix.com/company/compugen/news/compugen-participate-stifel-2025-healthcare-conference-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-participate-stifel-2025-healthcare-conference-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>HOLON, Israel, Nov. 4, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in</description>
</item>
<item>
<title>Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025</title>
<link>https://6ix.com/company/compugen/news/compugen-release-third-quarter-2025-results-monday-november-10-2025-2025-10-27</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-release-third-quarter-2025-results-monday-november-10-2025-2025-10-27</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>HOLON, Israel, Oct. 27, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in</description>
</item>
<item>
<title>Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025</title>
<link>https://6ix.com/company/compugen/news/compugen-present-pooled-analysis-com701-three-phase-1-trials-patients-platinum</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-present-pooled-analysis-com701-three-phase-1-trials-patients-platinum</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier setting of platinum</description>
</item>
<item>
<title>Compugen to Present at SITC 2025</title>
<link>https://6ix.com/company/compugen/news/compugen-present-sitc-2025-2025-10-06</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-present-sitc-2025-2025-10-06</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>HOLON, Israel, Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in</description>
</item>
<item>
<title>Compugen to Present Research at the Single Cell Genomics 2025 Conference</title>
<link>https://6ix.com/company/compugen/news/compugen-present-research-single-cell-genomics-2025-conference-2025-09-08</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-present-research-single-cell-genomics-2025-conference-2025-09-08</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>HOLON, ISRAEL, Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in</description>
</item>
<item>
<title>Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/compugen/news/compugen-present-hc-wainwright-27th-annual-global-investment-conference-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-present-hc-wainwright-27th-annual-global-investment-conference-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>HOLON, Israel, Aug. 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in</description>
</item>
<item>
<title>Compugen Reports Second Quarter 2025 Results</title>
<link>https://6ix.com/company/compugen/news/compugen-reports-second-quarter-2025-results-2025-08-06</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-reports-second-quarter-2025-results-2025-08-06</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025Pooled</description>
</item>
<item>
<title>Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025</title>
<link>https://6ix.com/company/compugen/news/compugen-present-pooled-analysis-com701-phase-1-trials-platinum-resistant-ovarian</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-present-pooled-analysis-com701-phase-1-trials-platinum-resistant-ovarian</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>HOLON, Israel, July 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in</description>
</item>
<item>
<title>Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025</title>
<link>https://6ix.com/company/compugen/news/compugen-release-second-quarter-2025-results-wednesday-august-6-2025-2025-07-23</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-release-second-quarter-2025-results-wednesday-august-6-2025-2025-07-23</guid>
<pubDate>Wed, 23 Jul 2025 04:00:00 GMT</pubDate>
<description>HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in</description>
</item>
<item>
<title>Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer</title>
<link>https://6ix.com/company/compugen/news/compugen-announces-first-patient-dosed-com701-global-platform-trial-platinum</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-announces-first-patient-dosed-com701-global-platform-trial-platinum</guid>
<pubDate>Mon, 21 Jul 2025 04:00:00 GMT</pubDate>
<description>Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancerTrial</description>
</item>
<item>
<title>Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences</title>
<link>https://6ix.com/company/compugen/news/compugen-present-ai-ml-driven-predictive-computational-research-upcoming</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-present-ai-ml-driven-predictive-computational-research-upcoming</guid>
<pubDate>Thu, 12 Jun 2025 04:00:00 GMT</pubDate>
<description>HOLON, Israel, June 12, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in</description>
</item>
<item>
<title>Compugen Reports First Quarter 2025 Results</title>
<link>https://6ix.com/company/compugen/news/compugen-reports-first-quarter-2025-results-2025-05-19</link>
<guid isPermaLink="true">https://6ix.com/company/compugen/news/compugen-reports-first-quarter-2025-results-2025-05-19</guid>
<pubDate>Mon, 19 May 2025 04:00:00 GMT</pubDate>
<description>Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human</description>
</item>
</channel>
</rss>